8-K: Cidara Therapeutics to Restate Prior Financial Statements Due to Tax Accounting Errors

Cidara Therapeutics will restate its financial statements from 2021 to 2023 due to errors in accounting for indirect taxes, leading to an understatement of liabilities and operating expenses.

Summary

• Cidara Therapeutics has determined that its previously issued financial statements for fiscal years 2021 and 2022, as well as quarterly reports in 2022 and 2023, should no longer be relied upon.
• The restatement is due to the company's failure to properly account for indirect taxes related to its supply chain activities.
• This resulted in an understatement of accrued liabilities and operating expenses in prior periods.
• The company estimates the restatement will include an accrued liability for indirect taxes, interest, and penalties of approximately $7.6 million and $11.5 million for 2021 and 2022, respectively.
• Operating expenses are expected to increase by approximately $3.7 million and $3.9 million for 2021 and 2022, respectively.
• The beginning accumulated deficit is expected to increase by approximately $3.9 million and $7.6 million for 2021 and 2022, respectively.
• Cidara believes the actual cash impact of these liabilities may be significantly less than the accrued amounts.
• The company has identified a material weakness in its internal control over financial reporting related to the evaluation of accounting standards and assessment of indirect tax liabilities.
• Cidara plans to file restated financial statements in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as soon as reasonably practicable.

Sentiment

Score: 3

Explanation: The document reveals significant accounting errors and a material weakness in internal controls, which is a negative signal for investors. While the company believes the cash impact may be less, the restatement itself is a major concern.

Positives

• The company believes the actual cash impact of the tax liabilities may be significantly less than the accrued amounts.
• Any accrued indirect taxes that are ultimately determined not to be due will be reversed in future periods.

Negatives

• Previously issued financial statements for 2021, 2022, and 2023 quarterly reports should no longer be relied upon.
• The company has identified a material weakness in its internal control over financial reporting.
• The restatement will increase accrued liabilities and operating expenses for the affected periods.

Risks

• The restatement analysis and financial close process may reveal additional issues beyond those related to supply chain activities.
• The amounts ultimately payable by the company may not be less than the indirect taxes accrual.
• The restatement could have a material impact on cash and cash equivalents.
• There is a risk that the company's disclosure controls and procedures were not effective at the reasonable assurance level.

Future Outlook

The company expects to file restated financial statements in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as soon as reasonably practicable. They also believe that the cash impact of the tax liabilities may be significantly less than the accrued amounts.

Management Comments

• Management recommended the restatement of prior financial statements to the Audit Committee.
• Management has concluded that the company's disclosure controls and procedures were not effective at the reasonable assurance level.
• Management believes that the indirect tax liability payable in cash could potentially be settled for an amount less than the indirect taxes accrual.

Industry Context

This announcement highlights the importance of accurate tax accounting, particularly for companies with complex supply chains and international operations. It is not uncommon for companies to restate financials due to accounting errors, but it can impact investor confidence.

Comparison to Industry Standards

• Restatements due to tax accounting errors are not uncommon in the pharmaceutical industry, especially for companies with global supply chains.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) have previously restated financials due to similar issues, although the specific circumstances and amounts may vary.
• The materiality of the restatement for Cidara will be assessed by investors in comparison to its overall financial position and market capitalization.
• The speed and transparency with which Cidara addresses the restatement will be compared to industry best practices.

Corporate Governance

Stakeholder Impact

• Shareholders will be impacted by the restatement of financial statements and the identified material weakness.
• Creditors may reassess their risk exposure to the company.
• Employees may be concerned about the company's financial stability and internal controls.

Next Steps

• The company plans to complete the restatement analysis.
• The company will present restated financial statements for the impacted periods in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
• The company will remediate the identified material weakness in internal control over financial reporting.

Key Dates

Keywords

restatement, financial statements, indirect taxes, accrued liabilities, operating expenses, internal control, material weakness, accounting, REZZAYO, rezafungin